Vaccitech Prepares For IPO, But AZ COVID-19 Vaccine Safety Fears Cloud Launch
Pipeline Candidates Use Same Platform
Executive Summary
The UK biotech aims to raise $100m, but will need to tackle safety concerns to secure a long-term future.
You may also be interested in...
Funding The Future: Accelerating The Long Walk To Innovation
In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.
Finance Watch: Roivant To Go Public In SPAC Merger, Raise $611m
Public Company Edition: Roivant’s deal sets its market cap at $7.3bn. Beyond the Werewolf and Vaccitech offerings, more drug developers are slated to go public during the first week of May. And in follow-on offerings, COMPASS Pathways raises $144m and Aldeyra brings in $125m.
Lessons Learnt From Aduhelm, Eisai Is Preaching Patience On Alzheimer’s Drug Leqembi
Eisai has spent 25 years looking for a breakthrough in Alzheimer’s and warns that healthcare systems need to undergo a major shift to accommodate its breakthrough drug.